Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Genistein 7-O-phosphate (G7P) is a water-soluble phosphate prodrug of the soy isoflavone genistein. It is generated through a biotransformation process using *Bacillus subtilis* var. natto BCRC80517 to overcome the poor aqueous solubility and low oral bioavailability of the parent compound. Upon oral administration, G7P is dephosphorylated by intestinal alkaline phosphatase to release active genistein, exhibiting approximately 3.7-fold higher oral bioavailability than genistein itself. Beyond its role as a prodrug, recent research has identified G7P as an antagonist of mechanosensitive cannabinoid receptor 1 (CB1) in endothelial cells. Preclinical studies have demonstrated its potential in preventing bone loss in osteoporosis models and reducing atherosclerotic plaque formation by reversing endothelial inflammation, oxidative stress, and endothelial-to-mesenchymal transition (EndMT) induced by disturbed blood flow.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on genistein 7-O-phosphate.